Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Open accessThe DOI matches its Crossref record; 275 of the 275 references it cites were found in a registry or an index.
Abstract
Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) are commonly recommended anti-HER2 target agents by the U.S. Food and Drug Administration. This review summarizes the most significant and updated research on clinical scenarios related to HER2-positive breast cancer management in order to revise the guidelines of everyday clinical practices. In this article, we present the data on anti-HER2 clinical research of neoadjuvant, adjuvant, and metastatic studies from the past 2 decades. We also highlight some of the promising strategies that should be critically considered. Lastly, this review lists some of the ongoing clinical trials, findings of which may soon be available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Bendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317
Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J. H., Tsai, Y.-F., Ratnayake, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt182 · Cited by 1,264
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., Castro, G., Untch, M., Smith, I., Gianni, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32616-2 · Cited by 1,035
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5730 · Cited by 978
Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 946
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00163-7 · Cited by 880
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 861
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., Chan, S., Jagiello-Gruszfeld, A., Kaufman, B., Crown, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 794
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 746
Biology of HER2 and Its Importance in Breast Cancer
Yarden, Y. (2001) · Oncology · doi:10.1159/000055396 · Cited by 737
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Symmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., Walls, A., Bousamra, A., Ramineni, M., Sinn, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1010 · Cited by 711
Diéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., Krop, I. E., Blackwell, K., Hoersch, S., Xu, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30312-1 · Cited by 667
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., & Bartlett, J. M. (2003) · The Journal of Pathology · doi:10.1002/path.1370 · Cited by 590
Martin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S. K. L., Mansi, J., Barrios, C. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30717-9 · Cited by 585
Self-citationChan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gokmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 561
Untch, M., Rezai, M., Loibl, S., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8451 · Cited by 556
Houssami, N., Macaskill, P., von Minckwitz, G., Marinovich, M. L., & Mamounas, E. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.023 · Cited by 548
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545
Hurvitz, S. A., Martin, M., Symmans, W. F., Jung, K. H., Huang, C.-S., Thompson, A. M., Harbeck, N., Valero, V., Stroyakovskiy, D., Wildiers, H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30716-7 · Cited by 534
Burstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8707 · Cited by 522
Sauter, G., Lee, J., Bartlett, J. M. S., Slamon, D. J., & Press, M. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8197 · Cited by 509
Untch, M., Fasching, P. A., Konecny, G. E., Hasmüller, S., Lebeau, A., Kreienberg, R., Camara, O., Müller, V., du Bois, A., Kühn, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4930 · Cited by 506
Doi, T., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., Shimizu, C., Shimoi, T., Kuboki, Y., Matsubara, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30604-6 · Cited by 505
Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., Weber, H. A., Heinzmann, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61094-6 · Cited by 497
Spector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493
Self-citationGianni, L., Eiermann, W., Semiglazov, V., Lluch, A., Tjulandin, S., Zambetti, M., Moliterni, A., Vazquez, F., Byakhov, M. J., Lichinitser, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70080-4 · Cited by 490
Robert, N., Leyland-Jones, B., Asmar, L., Belt, R., Ilegbodu, D., Loesch, D., Raju, R., Valentine, E., Sayre, R., Cobleigh, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1764 · Cited by 479
Loi, S., Giobbie-Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H., Jerusalem, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30812-x · Cited by 470
Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., Peintinger, F., Hanrahan, E. O., Sahin, A., Guray, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2025 · Cited by 467
Osborne, C. K., Shou, J., Massarweh, S., & Schiff, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.865s.11.2 · Cited by 462
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Möykkynen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4577 · Cited by 458
de Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., Untch, M., Jackisch, C., Lang, I., Smith, I., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70320-1 · Cited by 458
Self-citationUntch, M., Loibl, S., Bischoff, J., Eidtmann, H., Kaufmann, M., Blohmer, J.-U., Hilfrich, J., Strumberg, D., Fasching, P. A., Kreienberg, R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70397-7 · Cited by 451
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D., & Jenkins, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4744 · Cited by 438
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Guerrero-Zotano, A., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 417
Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., & Diéras, V. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu486 · Cited by 394
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Robidoux, A., Tang, G., Rastogi, P., Geyer, C. E., Azar, C. A., Atkins, J. N., Fehrenbacher, L., Bear, H. D., Baez-Diaz, L., Sarwar, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70411-x · Cited by 386
Brufsky, A. M., Mayer, M., Rugo, H. S., Kaufman, P. A., Tan-Chiu, E., Tripathy, D., Tudor, I. C., Wang, L. I., Brammer, M. G., Shing, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2962 · Cited by 386
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
MEDINA, P., & GOODIN, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.008 · Cited by 377
Piccart-Gebhart, M., Holmes, E., Baselga, J., de Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Armour, A., Pritchard, K. I., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1797 · Cited by 371
Self-citationRexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3747 · Cited by 368
Muthuswamy, S. K., Gilman, M., & Brugge, J. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.6845 · Cited by 363
Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study
Wu, Q., Li, J., Zhu, S., Wu, J., Chen, C., Liu, Q., Wei, W., Zhang, Y., & Sun, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15856 · Cited by 355
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351
Amiri-Kordestani, L., Blumenthal, G. M., Xu, Q. C., Zhang, L., Tang, S. W., Ha, L., Weinberg, W. C., Chi, B., Candau-Chacon, R., Hughes, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0012 · Cited by 351
Self-citationHER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 348
Llombart-Cussac, A., Cortés, J., Paré, L., Galván, P., Bermejo, B., Martínez, N., Vidal, M., Pernas, S., López, R., Muñoz, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30021-9 · Cited by 344
Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
Prowell, T. M., & Pazdur, R. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1205737 · Cited by 342
Gomez, H. L., Doval, D. C., Chavez, M. A., Ang, P. C.-S., Aziz, Z., Nag, S., Ng, C., Franco, S. X., Chow, L. W. C., Arbushites, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0590 · Cited by 338
Pivot, X., Romieu, G., Debled, M., Pierga, J.-Y., Kerbrat, P., Bachelot, T., Lortholary, A., Espié, M., Fumoleau, P., Serin, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70225-0 · Cited by 337
Ma, F., Ouyang, Q., Li, W., Jiang, Z., Tong, Z., Liu, Y., Li, H., Yu, S., Feng, J., Wang, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00108 · Cited by 334
Self-citationHER2 in Breast Cancer: A Review and Update
Krishnamurti, U., & Silverman, J. F. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000015 · Cited by 328
Sjögren, S., Inganäs, M., Lindgren, A., Holmberg, L., & Bergh, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.462 · Cited by 327
Gabos, Z., Sinha, R., Hanson, J., Chauhan, N., Hugh, J., Mackey, J. R., & Abdulkarim, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0250 · Cited by 321
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
Ciruelos Gil, E. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.004 · Cited by 314
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 306
Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study
Martin, A. M., Cagney, D. N., Catalano, P. J., Warren, L. E., Bellon, J. R., Punglia, R. S., Claus, E. B., Lee, E. Q., Wen, P. Y., Haas-Kogan, D. A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0001 · Cited by 301
Spielmann, M., Roché, H., Delozier, T., Canon, J.-L., Romieu, G., Bourgeois, H., Extra, J.-M., Serin, D., Kerbrat, P., Machiels, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0946 · Cited by 298
Burris, H. A. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_3-10 · Cited by 295
Andersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., Karlsson, P., Tange, U. B., Sørensen, P. G., Møller, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8213 · Cited by 294
Iwata, T. N., Ishii, C., Ishida, S., Ogitani, Y., Wada, T., & Agatsuma, T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0749 · Cited by 291
Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain
Gril, B., Palmieri, D., Bronder, J. L., Herring, J. M., Vega-Valle, E., Feigenbaum, L., Liewehr, D. J., Steinberg, S. M., Merino, M. J., Rubin, S. D., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn216 · Cited by 283
Tolaney, S. M., Guo, H., Pernas, S., Barry, W. T., Dillon, D. A., Ritterhouse, L., Schneider, B. P., Shen, F., Fuhrman, K., Baltay, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00066 · Cited by 278
Ross, J. S., & Fletcher, J. A. (1998) · The Oncologist · doi:10.1634/theoncologist.3-4-237 · Cited by 260
Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0962 · Cited by 259
Wülfing, P., Borchard, J., Buerger, H., Heidl, S., Zänker, K. S., Kiesel, L., & Brandt, B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2087 · Cited by 258
Mechanism of action of trastuzumab and scientific update
BASELGA, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90276-3 · Cited by 258
Valero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., von Minckwitz, G., Roche, H., Martin, M., Crown, J., Mackey, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6450 · Cited by 255
Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245
Pivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242
Leyland-Jones, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8481 · Cited by 233
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
Perez, E. A., Reinholz, M. M., Hillman, D. W., Tenner, K. S., Schroeder, M. J., Davidson, N. E., Martino, S., Sledge, G. W., Harris, L. N., Gralow, J. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2154 · Cited by 233
Breast Cancer: Major Risk Factors and Recent Developments in Treatment
Majeed, W., Aslam, B., Javed, I., Khaliq, T., Muhammad, F., Ali, A., & Raza, A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.8.3353 · Cited by 229
Ignatiadis, M., Kallergi, G., Ntoulia, M., Perraki, M., Apostolaki, S., Kafousi, M., Chlouverakis, G., Stathopoulos, E., Lianidou, E., Georgoulias, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4758 · Cited by 229
Ma, F., Li, Q., Chen, S., Zhu, W., Fan, Y., Wang, J., Luo, Y., Xing, P., Lan, B., Li, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.6179 · Cited by 228
Self-citationLi, X., Yang, C., Wan, H., Zhang, G., Feng, J., Zhang, L., Chen, X., Zhong, D., Lou, L., Tao, W., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.01.021 · Cited by 227
Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw197 · Cited by 227
Huober, J., Fasching, P. A., Barsoum, M., Petruzelka, L., Wallwiener, D., Thomssen, C., Reimer, T., Paepke, S., Azim, H. A., Ragosch, V., et al. (2012) · The Breast · doi:10.1016/j.breast.2011.07.006 · Cited by 223
Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
Albanell, J., Codony, J., Rovira, A., Mellado, B., & Gascón, P. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0081-0_21 · Cited by 219
Trastuzumab-containing regimens for metastatic breast cancer
Balduzzi, S., Mantarro, S., Guarneri, V., Tagliabue, L., Pistotti, V., Moja, L., & D'Amico, R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006242.pub2 · Cited by 218
Peoples, G. E., Gurney, J. M., Hueman, M. T., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., Shriver, C. D., Ioannides, C. G., & Ponniah, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.047 · Cited by 216
Burstein, H. J., Keshaviah, A., Baron, A. D., Hart, R. D., Lambert‐Falls, R., Marcom, P. K., Gelman, R., & Winer, E. P. (2007) · Cancer · doi:10.1002/cncr.22885 · Cited by 214
Burstein, H. J., Storniolo, A. M., Franco, S., Forster, J., Stein, S., Rubin, S., Salazar, V. M., & Blackwell, K. L. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm601 · Cited by 203
Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
Taskar, K. S., Rudraraju, V., Mittapalli, R. K., Samala, R., Thorsheim, H. R., Lockman, J., Gril, B., Hua, E., Palmieri, D., Polli, J. W., et al. (2012) · Pharmaceutical Research · doi:10.1007/s11095-011-0601-8 · Cited by 202
Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D., Schaefer, G., Miller, K., Andre, F., Burris, H. A., Albain, K. S., Harbeck, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0358 · Cited by 198
Araki, K., & Miyoshi, Y. (2018) · Breast Cancer · doi:10.1007/s12282-017-0812-x · Cited by 196
Lin, N. U., Winer, E. P., Wheatley, D., Carey, L. A., Houston, S., Mendelson, D., Munster, P., Frakes, L., Kelly, S., Garcia, A. A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2003-y · Cited by 195
Coon, J. S., Marcus, E., Gupta-Burt, S., SEELIG, S. A., Jacobson, K., Chen, S., RENTA, V., Fronda, G., & Preisler, H. D. (2002) · PubMed · Cited by 193
Ramakrishna, N., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Giordano, S. H., Gonzalez-Angulo, A. M., Kirshner, J. J., Krop, I., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0955 · Cited by 191
Altundag, K., Bondy, M. L., Mirza, N. Q., Kau, S., Broglio, K., Hortobagyi, G. N., & Rivera, E. (2007) · Cancer · doi:10.1002/cncr.23088 · Cited by 189
Schwartzberg, L. S., Franco, S. X., Florance, A., O'Rourke, L., Maltzman, J., & Johnston, S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0240 · Cited by 188
PI3K/Akt/mTOR inhibitors in breast cancer
Joycelyn, Jx, Lee, Kiley, Loh, K. W.-J., Yoon-Sim, & Yap (2015) · 癌症生物学与医学:英文版 · Cited by 185
Gurney, J. M., Hueman, M. T., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., Shriver, C. D., Ioannides, C. G., Ponniah, S., & Peoples, G. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2575 · Cited by 183
Peoples, G. E., Holmes, J. P., Hueman, M. T., Mittendorf, E. A., Amin, A., Khoo, S., Dehqanzada, Z. A., Gurney, J. M., Woll, M. M., Ryan, G. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1448 · Cited by 182
von Minckwitz, G., Schwedler, K., Schmidt, M., Barinoff, J., Mundhenke, C., Cufer, T., Maartense, E., de Jongh, F. E., Baumann, K. H., Bischoff, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.021 · Cited by 181
Fallowfield, L. J., Bliss, J. M., Porter, L. S., Price, M. H., Snowdon, C. F., Jones, S. E., Coombes, R. C., & Hall, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3654 · Cited by 178
Morikawa, A., Peereboom, D. M., Thorsheim, H. R., Samala, R., Balyan, R., Murphy, C. G., Lockman, P. R., Simmons, A., Weil, R. J., Tabar, V., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou141 · Cited by 173
HER-2/neu expression in primary and metastatic breast cancer
Lower, E. E., Glass, E., Blau, R., & Harman, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9931-6 · Cited by 171
Freedman, R. A., Gelman, R. S., Wefel, J. S., Melisko, M. E., Hess, K. R., Connolly, R. M., Van Poznak, C. H., Niravath, P. A., Puhalla, S. L., Ibrahim, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0343 · Cited by 171
Buzdar, A. U., Suman, V. J., Meric-Bernstam, F., Leitch, A. M., Ellis, M. J., Boughey, J. C., Unzeitig, G., Royce, M., McCall, L. M., Ewer, M. S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70502-3 · Cited by 170
Pertuzumab: new hope for patients with HER2-positive breast cancer
Capelan, M., Pugliano, L., De Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C., Loi, S., & Piccart-Gebhart, M. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds328 · Cited by 166
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Canonici, A., Gijsen, M., Mullooly, M., Bennett, R., Bouguern, N., Pedersen, K., O’Brien, N. A., Roxanis, I., Li, J.-L., Bridge, E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1148 · Cited by 164
Olson, E. M., Abdel‐Rasoul, M., Maly, J., Wu, C. S.-Y., Lin, N., & Shapiro, C. L. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt036 · Cited by 162
Mavroudis, D., Saloustros, E., Malamos, N., Kakolyris, S., Boukovinas, I., Papakotoulas, P., Kentepozidis, N., Ziras, N., & Georgoulias, V. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv213 · Cited by 162
Zhao, J., Wu, R., Au, A., Marquez, A., Yu, Y., & Shi, Z. (2002) · Modern Pathology · doi:10.1038/modpathol.3880582 · Cited by 160
Borges, V. F., Ferrario, C., Aucoin, N., Falkson, C., Khan, Q., Krop, I., Welch, S., Conlin, A., Chaves, J., Bedard, P. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1812 · Cited by 160
Harbeck, N., Huang, C., Hurvitz, S. A., Yeh, D., Shao, Z., Im, S., Jung, K. H., Shen, K., Ro, J., Jassem, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00540-9 · Cited by 156
Self-citationConte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy414 · Cited by 156
Esteva, F. J., Cheli, C. D., Fritsche, H. A., Fornier, M. N., Slamon, D. J., Thiel, R. P., Lüftner, D., & Ghani, F. (2005) · Breast Cancer Research · doi:10.1186/bcr1020 · Cited by 154
Slamon, D., EIERMANN, W., Robert, N., Giermek, J., Martín, M., Jasiówka, M., Mackey, J., Chan, A., Liu, M.-C., Pintér, T., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s5-04 · Cited by 154
Lynce, F. C., Barac, A., Geng, X., Dang, C. T., Yu, A. F., Smith, K. L., Gallagher, C., Pohlmann, P., Nunes, R., Herbolsheimer, P. M., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05191-2 · Cited by 154
Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M., Nyandoto, P., Villman, K. K., Halonen, P., Granstam-Björneklett, H., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1380 · Cited by 151
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 147
Xia, W., Husain, I., Liu, L., Bacus, S., Saini, S., Spohn, J., Pry, K., Westlund, R., Stein, S. H., & Spector, N. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2101 · Cited by 146
Anti-HER2 vaccines: new prospects for breast cancer therapy
Ladjemi, M. Z., Jacot, W., Chardès, T., Pèlegrin, A., & Navarro‐Teulon, I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0869-2 · Cited by 145
PI3K/Akt/mTOR inhibitors in breast cancer.
Lee, J. J. X., Loh, K. W.-J., & Yap, Y. S. (2015) · PubMed · doi:10.7497/j.issn.2095-3941.2015.0089 · Cited by 142
Rothé, F., Silva, M. J., Venet, D., Campbell, C., Bradburry, I., Rouas, G., de Azambuja, E., Maetens, M., Fumagalli, D., Rodrik-Outmezguine, V. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2521 · Cited by 138
HER2gene status in primary breast cancers and matched distant metastases
Tapia, C., Savic, S., Wagner, U., Schönegg, R., Novotny, H., Grilli, B., Herzog, M., Barascud, A., Zlobec, I., Cathomas, G., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1676 · Cited by 133
Prat, A., Cheang, M. C. U., Galván, P., Nuciforo, P., Paré, L., Adamo, B., Muñoz, M., Viladot, M., Press, M. F., Gagnon, R., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0922 · Cited by 132
Arciero, C. A., Guo, Y., Jiang, R., Behera, M., O'Regan, R. M., Peng, L., & Li, X. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.02.001 · Cited by 132
Coudert, B. P., Largillier, R., Arnould, L., Chollet, P. J. M., Campone, M., Coeffic, D., Priou, F., Gligorov, J., Pérez-Martin, X., Trillet-Lenoir, V. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9994 · Cited by 131
HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation
Vaught, D. B., Stanford, J. C., Young, C., Hicks, D. J., Wheeler, F., Rinehart, C., Sánchez, V., Koland, J., Muller, W. J., Arteaga, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3594 · Cited by 129
Wardley, A. M., Pivot, X. B., Morales-Vásquez, F., Zetina, L. M., Gauí, M. D. F. D., Reyes, D. O., Jassem, J., Barton, C. M., Button, P., Hersberger, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6531 · Cited by 127
Activity of T-DM1 in Her2-positive breast cancer brain metastases
Bartsch, R., Berghoff, A. S., Vogl, U. M., Rudas, M., Bergen, E. S., Dubsky, P. C., Dieckmann, K. U., Pinker, K., Bagó-Horváth, Z., Galid, A., et al. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9740-3 · Cited by 123
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
Gianni, L., Salvatorelli, E., & Minotti, G. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0013-5 · Cited by 122
Hofmann, M., Stoss, O., Gaiser, T., Kneitz, H., Heinmöller, P., Gutjahr, T., Kaufmann, M., Henkel, T. O., & Rüschoff, J. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.043562 · Cited by 122
Urruticoechea, A., Rizwanullah, M., Im, S., Ruiz, A. C. S., Láng, I., Tomasello, G., Douthwaite, H., Črnjević, T. B., Heeson, S., Eng‐Wong, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.6267 · Cited by 120
Hanna, W. M., & Kwok, K. (2006) · Modern Pathology · doi:10.1038/modpathol.3800555 · Cited by 119
Bachelot, T., Ciruelos, E., Schneeweiß, A., Puglisi, F., Peretz‐Yablonski, T., Bondarenko, I., Paluch–Shimon, S., Wardley, A. M., Merot, J.-L., Toit, Y. D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz061 · Cited by 116
Awada, A. H., Dirix, L. Y., Manso, L., Xu, B., Luu, T., Dieras, V. C., Hershman, D. L., Agrapart, V., Ananthakrishnan, R., & Starosławska, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds284 · Cited by 115
Self-citationJacot, W., Tostivint, E. P., Frenel, J., Guiu, S., Lévy, C., Heudel, P., Bachelot, T., D’Hondt, V., Darlix, A., Firmin, N., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3828-6 · Cited by 115
Petrelli, F., Ghidini, M., Lonati, V., Tomasello, G., Borgonovo, K., Ghilardi, M., Cabiddu, M., & Barni, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.024 · Cited by 115
Svane, I. M., Pedersen, A. E., Johnsen, H. E., Nielsen, D. L., Kamby, C., Gaarsdal, E., Nikolajsen, K., Buus, S., & Claësson, M. H. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0493-5 · Cited by 114
Immunohistochemical categorisation of ductal carcinoma in situ of the breast
Meijnen, P., Peterse, J. L., Antonini, N. F., Rutgers, E. J. T., & van de Vijver, M. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604112 · Cited by 111
Yu, S., Liu, Q., Han, X., Qin, S., Zhao, W., Li, A., & Wu, K. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0091-4 · Cited by 108
Pinto, A. C., Ades, F., de Azambuja, E., & Piccart, M. J. (2013) · The Breast · doi:10.1016/j.breast.2013.07.029 · Cited by 107
Extra, J.-M., Antoine, É.-C., Vincent‐Salomon, A., Delozier, T., Kerbrat, P., Béthune-Volters, A., Guastalla, J., Spielmann, M., Mauriac, L., Misset, J. L., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0029 · Cited by 107
Arnould, L., Arveux, P., Couturier, J., Gelly-Marty, M., Loustalot, C., Ettore, F., Sagan, C., Antoine, M., Penault-Llorca, F. M., Vasseur, B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3022 · Cited by 106
Lennon, S., Barton, C. M., Banken, L., Gianni, L., Marty, M. E., Baselga, J. M., & Leyland-Jones, B. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.8351 · Cited by 103
Montemurro, F., Ellis, P., Antón, A., Wuerstlein, R., Delaloge, S., Bonneterre, J. M., Quénel-Tueux, N., Linn, S. C., Irahara, N., Donica, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.022 · Cited by 101
Her2 cross talk and therapeutic resistance in breast cancer
Laura, M. B. (2008) · Frontiers in bioscience · doi:10.2741/2978 · Cited by 100
Gown, A. M., Goldstein, L. C., Barry, T. S., Kussick, S. J., Kandalaft, P. L., Kim, P. M., & Tse, C. C. H. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.83 · Cited by 100
Ariga, R., Zarif, A., Korasick, J., Reddy, V., Siziopikou, K. P., & Gattuso, P. (2005) · The Breast Journal · doi:10.1111/j.1075-122x.2005.21463.x · Cited by 99
Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Pierobon, M., Ramos, C., Wong, S., Hodge, K. A., Aldrich, J., Byron, S., Anthony, S. P., Robert, N. J., Northfelt, D. W., Jahanzeb, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2656 · Cited by 98
Zhang, D., Pal, A., Bornmann, W. G., Yamasaki, F., Esteva, F. J., Hortobágyi, G. N., Bartholomeusz, C., & Ueno, N. T. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0168 · Cited by 97
Targeted Therapies for Brain Metastases from Breast Cancer
Venur, V. A., & Leone, J. P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091543 · Cited by 96
Wang, H., Zhang, C., Zhang, J., Kong, L., Zhu, H., & Yu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.14300 · Cited by 95
Jäger, M., Schoberth, A., Ruf, P., Hess, J., & Lindhofer, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2861 · Cited by 94
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
Boyraz, B., Şendur, M. A. N., Aksoy, S., Babacan, T., Roach, E. C., Kızılarslanoğlu, M. C., Petekkaya, İ., & Altundağ, K. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.775113 · Cited by 91
Inoue, K., Nakagami, K., Mizutani, M., Hozumi, Y., Fujiwara, Y., Masuda, N., Tsukamoto, F., Saito, M., Miura, S., Eguchi, K., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0498-7 · Cited by 89
Madarnas, Y., Trudeau, M., Franek, J. A., McCready, D. R., Pritchard, K. I., & Messersmith, H. J. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.013 · Cited by 89
McArthur, H. L., Mahoney, K. M., Morris, P. G., Patil, S. N., Jacks, L. M., Howard, J., Norton, L., & Hudis, C. A. (2011) · Cancer · doi:10.1002/cncr.26171 · Cited by 85
Limentani, S. A., Brufsky, A., Erban, J. K., Jahanzeb, M., & LEWIS, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3306 · Cited by 85
Blackwell, K., Miles, D. W., Gianni, L., Krop, I. E., Welslau, M., Baselga, J. M., Pegram, M. D., Oh, D., Dieras, V. C., Olsen, S. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.lba1 · Cited by 84
Systematic Review of HER2 Breast Cancer Testing
Cuadros, M., & Villegas, R. (2008) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e318169fc1c · Cited by 84
Peddi, P. F., & Hurvitz, S. A. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014539183 · Cited by 84
Cardiac Toxicity of ErbB2-Targeted Therapies: What Do We Know?
Perez, E. A. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.s.007 · Cited by 83
Saleem, A., Searle, G. E., Kenny, L. M., Huiban, M., Kozlowski, K., Waldman, A. D., Woodley, L., Palmieri, C., Lowdell, C. P., Kaneko, T., et al. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0103-5 · Cited by 83
Brollo, J., Curigliano, G., Disalvatore, D., Marrone, B. F., Criscitiello, C., Bagnardi, V., Kneubil, M. C., Fumagalli, L. A. M., Locatelli, M., Manunta, S., et al. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.009 · Cited by 81
Bullock, K., & Blackwell, K. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0204 · Cited by 80
Beyond trastuzumab: New treatment options for HER2-positive breast cancer
Saini, K. S., Azim, H. A., Metzger, O., Loi, S., Sotiriou, C. P., de Azambuja, E., & Piccart, M. J. (2011) · The Breast · doi:10.1016/s0960-9776(11)70289-2 · Cited by 80
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
“As reported in Her2+ breast cancer patients treated with Trastuzumab and chemotherapy, the treatment-induced epitope spreading was characterized by increased antibody responses not only to the tumor antigen Her2, but also to endogenous CEA, insulin-like growth factor-binding protein 2 (IGFBP2), and p53 (521).”
BackgroundInfluentialBreast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
van der Koog, L., Gandek, T. B., & Nagelkerke, A. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202100639 · Cited by 418
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126806 · Cited by 406
Andersson, A., Larsson, L., Stenbeck, L., Salmén, F., Ehinger, A., Wu, S. Z., Al-Eryani, G., Roden, D., Swarbrick, A., Borg, Å., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26271-2 · Cited by 404
Metadata
- Authors
- Wang, J., & Xu, B.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2019-09-13
- Volume
- 4
- Issue
- 1
- Pages
- 34-34
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W2972399366
- Cited by
- 393
- References
- 275
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.